Lessons Learned from Pharmaceutical Nanomaterials - Safety of Nanomaterials along Their Lifecycle - page 134

Wang, D. and S. R. Goldring (2011) The bone, the joints and the Balm of Gilead. Mol Pharm
8 (4):991-993.
Wang, D., S. C. Miller, M. Sima, D. Parker, H. Buswell, K. C. Goodrich, P. Kopeckova, and
J. Kopecek (2004) The arthrotropism of macromolecules in adjuvant-induced arthritis
rat model: A preliminary study. Pharm Res 21 (10):1741-1749.
Wawer, I. and B. Diehl (2011) NMR spectroscopy in pharmaceutical analysis. Elsevier:
Amsterdam.
Weyermann, J., D. Lochmann, and A. Zimmer (2005) A practical note on the use of cytotoxic-
ity assays. Int J Pharm 288 (2):369-376.
Wohlfart, S., S. Gelperina, and J. Kreuter (2012) Transport of drugs across the blood-brain
barrier by nanoparticles. J Control Release 161 (2):264-273.
Wong, G. (2009) Biotech scientists bank on big pharma's biologics push. Nat Biotechnol
27:293-296.
Working, P. K., M. S. Newman, T. Sullivan, and J. Yarrington (1999) Reduction of the car-
diotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating,
pegylated liposomes. J Pharmacol Exp Ther 289 (2):1128-233.
Wunder, A., U. Muller-Ladner, E. H. Stelzer, J. Funk, E. Neumann, G. Stehle, T. Pap, H. Sinn,
S. Gay, and C. Fiehn (2003) Albumin-based drug delivery as novel therapeutic approach
for rheumatoid arthritis. J Immunol 170 (9):4793-4801.
Yuan, F., M. Dellian, D. Fukumura, M. Leunig, D. A. Berk, V. P. Torchilin, and R. K. Jain
(1995) Vascular permeability in a human tumor xenograft: Molecular size dependence
and cutoff size advances in brief vascular permeability in a human tumor xenograft:
Molecular size dependence and cutoff size. Cancer Res 55 (17):3752-3756.
Yuan, F., L.-D. Quan, L. Cui, S. R. Goldring, and D. Wang (2012) Development of macromo-
lecular prodrug for rheumatoid arthritis. Adv Drug Deliv Rev 64 (12):1205-1219.
Zimmerman, J. J., G. M. Ferron, H-K Lim, and V. Parker (1999) The effect of a high-fat
meal on the oral bioavailability of the immunosuppressant sirolimus (rapamycin). J Clin
Pharmacol 39 (11):1155-1161.
Zolnik, B. S. and N. Sadrieh (2009) Regulatory perspective on the importance of ADME
assessment of nanoscale material containing drugs. Adv Drug Deliv Rev 61 (6):422-427.